Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-03-19, Stock:NVS, The news for the past five days is as follows:
2019-03-12: NEWS1: [$$] Novartis, Volkswagen Focus on Improving Culture Following Compliance Setbacks.NEWS2: How This Looming Patent Battle Could Challenge Bristol-Celgene Deal.NEWS3: Roche's (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer.NEWS4: Roche's (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer.NEWS5: Allergan Announces FDA Acceptance of Migraine Candidate NDA.NEWS6: Allergan Announces FDA Acceptance of Migraine Candidate NDA.NEWS7: Allergan Announces FDA Acceptance of Migraine Candidate NDA.NEWS8: Roche's (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer.NEWS9: Why Novartis is a Top 10 SAFE International Dividend Stock (NVS).NEWS10: Why Novartis is a Top 10 SAFE International Dividend Stock (NVS).
2019-03-13: nan
2019-03-14: NEWS1: Roche Receives EC Approval for Label Expansion of Hemlibra.NEWS2: Roche Receives EC Approval for Label Expansion of Hemlibra.NEWS3: Roche Receives EC Approval for Label Expansion of Hemlibra.NEWS4: Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades.NEWS5: Novartis generics boss quits amid conjecture over business's future.NEWS6: [$$] Head of Novartis generic drugs business steps down.
2019-03-15: NEWS1: Roche Gets Approval for Label Expansion of MabThera in Europe.NEWS2: Roche Gets Approval for Label Expansion of MabThera in Europe.NEWS3: Roche Gets Approval for Label Expansion of MabThera in Europe.NEWS4: The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA.
2019-03-18: NEWS1: Alnylam's (ALNY) Impressive Pipeline Drives Share Price.NEWS2: Novartis' (NVS) Alcon Acquired PowerVision for $285 Million.NEWS3: Novartis' (NVS) Alcon Acquired PowerVision for $285 Million.NEWS4: Novartis' (NVS) Alcon Acquired PowerVision for $285 Million.

Answer: Decrease